copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Alexion Global Site As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases
Alexion inks deal to acquire Achillion for $930M upfront Alexion has struck a deal to buy Achillion for $930 million upfront The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare
Alexion Completes Acquisition of Achillion - Business Wire Alexion will continue development of Achillion’s oral Factor D inhibitor portfolio, which includes two clinical-stage medicines-in-development – danicopan (ACH-4471) and ACH-5228 – as well as
Alexion to pay $930m to acquire Achillion Pharmaceuticals Alexion Pharmaceuticals has agreed to acquire Achillion Pharmaceuticals for an upfront payment of around $930m, or $6 30 per share Achillion Pharmaceuticals develops Factor D inhibitor therapies for complement alternative pathway-mediated rare diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G)
Alexion Pharmaceuticals wraps up $930m acquisition of Achillion Achillion secured a breakthrough therapy designation for danicopan in combination with a C5 monoclonal antibody to treat patients with PNH who are sub-optimal responders to a C5 inhibitor alone
Achillion shareholders approve $930M Alexion takeover Shareholders of Achillion Pharmaceuticals have overwhelmingly approved the company’s takeover by fellow New Haven-born drug maker Alexion Pharmaceuticals for $930 million Achillion said
Alexion dumps ex-Achillion C3G program after seeing phase 2 data Alexion has scrapped development of the lead asset acquired in its $930 million takeover of Achillion Pharmaceuticals in one indication The action follows a “suboptimal” clinical response in two